Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
Circulation · 14.02.2023 · 147 (7) · 597-610
DOI: 10.1161/circulationaha.122.061559 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Circulation, erschienen am 14.02.2023. Verfasst von Leslie Cho und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic, OH (L.C.). Hauptthemen laut MEDLINE: Estrogen Replacement Therapy, Cardiovascular Diseases. Die Arbeit wurde bisher 212-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiolovascular Disease in Women Committee, along with leading gynecologists, women’s health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cleveland Clinic, OH (L.C.).
- University of Florida College of Medicine-Jacksonville (A.M.K.).
- Mayo Clinic, Jacksonville, FL (S.S.F.).
- Mayo Clinic, Rochester, MN (S.N.H., C.L.S.).
- Massachusetts General Hospital, Boston (E.S.L., N.S., J.L.S.).
- University of Washington Medical Center, Seattle (N.P.).
ORCID-Profile: Leslie Cho, Sharonne N Hayes, Emily S Lau, Nandita Scott, Chrisandra L Shufelt, Kathryn J Lindley
Förderung
- NHLBI NIH HHS
Zitieren
APA
Cho, L., Kaunitz, A. M., Faubion, S. S., Hayes, S. N., Lau, E. S., Pristera, N., Scott, N., Shifren, J. L., Shufelt, C. L., Stuenkel, C. A., Lindley, K. J., & ACC CVD in Women Committee (2023). Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?. Circulation, 147(7), 597-610. https://doi.org/10.1161/circulationaha.122.061559
Vancouver
Cho L, Kaunitz AM, Faubion SS, Hayes SN, Lau ES, Pristera N, et al. Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?. Circulation. 2023;147(7):597-610. doi:10.1161/circulationaha.122.061559
BibTeX
@article{Cho2023,
author = {Cho, Leslie and Kaunitz, Andrew M and Faubion, Stephanie S and Hayes, Sharonne N and Lau, Emily S and Pristera, Nicole and Scott, Nandita and Shifren, Jan L and Shufelt, Chrisandra L and Stuenkel, Cynthia A and Lindley, Kathryn J and ACC CVD in Women Committee, ACC CVD in Women Committee},
title = {Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?},
journal = {Circulation},
year = {2023},
volume = {147},
number = {7},
pages = {597--610},
doi = {10.1161/circulationaha.122.061559}
}
EUVIMED